tablets "Yuperio" are applied to treatment of chronic heart failure at adult patients with reduced fraction of emission of a left ventricle.

Structure

One tablet contains (active ingredients) of 97.2 mg of a sakubitril and 102.8 mg of a valsartan (in the form of a complex of sodium salt of a sakubitril and a valsartan).

Excipients: cellulose microcrystalline, the hydroxypropyl cellulose low-substituted krospovidon, magnesium stearate, talc, silicon dioxide colloidal, a gipromelloza, the titan dioxide (E 171), a macrogoal 4000, iron oxide, red (E 172), iron oxide, black (E 172).

Contraindication

• hypersensitivity to active ingredient or to any of excipients;
• simultaneous use with APF inhibitors; Yuperio can be accepted if from the moment of cancellation of APF inhibitor there passed not less than 36 hours;
• existence in the anamnesis of a Quincke's disease at use of APF or SCONCE inhibitors;
• hereditary or idiopathic Quincke's disease;
• simultaneous use with the medicines containing aliskiren, to patients with diabetes or to patients with a renal failure (rShKF <60 ml/minute / 1.73 m ² );
• abnormal liver function of heavy degree, biliary cirrhosis and cholestasia;
• second and third pregnancy trimester.

by

for oral administration. Time of administration of medicament of Yuperio does not depend on meal time. To swallow tablets entirely and to wash down with a glass of water.

Recommended initial dose of Yuperio - on one tablet of 100 mg 2 times a day, except for the situations described below. The dose needs to be doubled in 2-4 weeks of reception so that the dose made one tablet of 200 mg two times a day on condition of good tolerance the patient.

If at patients the intolerance develops (the systolic arterial blood pressure (SABP) ≤ 95 mm of a mercury column, symptomatic hypotension, a hyperpotassemia, a renal failure) it is recommended to correct combination therapy, to temporarily lower a dose or to stop therapy by the medicament "Yuperio".

Information on treatment of patients who do not accept APF or SCONCE inhibitors or accept them in low doses, it is limited. Therefore for such category of patients the recommended dose makes 50 mg 2 times a day with slow increase in a dose (doubling of a daily dose of 1 times in 3-4 weeks).

treatment of patients with the level of serumal potassium> 5.4 mmol/l or is not recommended to begin

with SAT <100 mm of a mercury column. The initial dose of 50 mg two times a day is recommended for patients with SABP ≥ 100-110 mm of a mercury column. Yuperio should not be applied with APF or SCONCE inhibitor. Considering potential risk of developing a Quincke's disease at simultaneous use with APF inhibitor medicament it is not necessary to use if from the moment of cancellation of APF inhibitor there did not pass at least 36 hours.

Valsartan in the form of the complex salt which is contained in the medicament "Yuperio" has higher bioavailability in comparison with valsartany which contains in other tableted drugs.

If the patient missed administration of drug, it should accept the following dose in due time.

Feature of use

Pregnant

is not recommended to accept Yuperio during the first trimester of pregnancy, and during the second and third trimesters of pregnancy medicament is contraindicated to use.

Considering potential risk of development of side reactions at the children who are on breastfeeding it is not recommended to use medicament during feeding by a breast.

Data on influence of Yuperio on a human body are absent. During the medicament researches on males and females of rats disturbances of reproductive function were revealed.

Safety and efficiency of use of Yuperio are not established to children (aged up to 18 years) by

. Data are absent.

Drivers

Due to the possible developing of dizziness or increased fatigue should be careful at control of motor transport or work with other mechanisms.

Overdose

Data on overdose of Yuperio medicine at the person.

.

Most probable symptom of overdose is the profound lowering of arterial pressure caused by antihypertensive effect of active ingredients. In this case symptomatic treatment is recommended. Medicine conclusion probability during a hemodialysis is extremely small, considering high linking with proteins of blood plasma.

Side effects

during therapy by the medicament "Yuperio" it was most often reported about such side reactions as hypotension, a hyperpotassemia and a renal failure. There were messages that the patients accepting Yuperio had a Quincke's disease.

to Store

in original packing for protection against moisture at a temperature not above 30 °C, out of children's reach.

Expiration date - 36 months.